Mega Genomics (HKSE:06667) Debt-to-EBITDA : 1.44 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mega Genomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$13.7 Mil. Mega Genomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$39.4 Mil. Mega Genomics's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$36.9 Mil. Mega Genomics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 1.44.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Mega Genomics's Debt-to-EBITDA or its related term are showing as below:

HKSE:06667' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.03 Med: 0.93 Max: 2.56
Current: 0.93

During the past 5 years, the highest Debt-to-EBITDA Ratio of Mega Genomics was 2.56. The lowest was -2.03. And the median was 0.93.

HKSE:06667's Debt-to-EBITDA is ranked better than
67.65% of 102 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.775 vs HKSE:06667: 0.93

Mega Genomics Debt-to-EBITDA Historical Data

The historical data trend for Mega Genomics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics Debt-to-EBITDA Chart

Mega Genomics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

2.56

1.35

0.10

-2.03

0.93

Mega Genomics Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial			0.10	0.20	-0.12	0.15	1.44

Competitive Comparison of Mega Genomics's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Mega Genomics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mega Genomics's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Mega Genomics's Debt-to-EBITDA falls into.

Mega Genomics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mega Genomics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(13.703	+	39.413)	/	57.337
	=	0.93

Mega Genomics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(13.703	+	39.413)	/	36.926
	=	1.44

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Mega Genomics (HKSE:06667) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Mega Genomics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Mega Genomics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Mega Genomics (HKSE:06667) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

North Garden Road, 401 Health Work, Haidian District, Beijing, CHN

Website

https://www.megagenomics.cn

Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening and infectious disease diagnosis, to meet consumers' growing preventive medical needs.

Executives

Guo Meiling	2101 Beneficial owner
Lin Lin	2101 Beneficial owner
Yu Rong	2501 Other
Infinite Galaxy Health Limited	2101 Beneficial owner
Mei Nian Investment Limited	2101 Beneficial owner
Kastle Limited	2501 Other
Mega Marvelous Limited	2501 Other
Yurong Technology Limited	2101 Beneficial owner
Niu Zhencai	2201 Interest of corporation controlled by you
Mei Nian Da Jian Kang Chan Ye Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si	2501 Other
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner

Mega Genomics (HKSE:06667) Headlines

No Headlines